Log in to save to my catalogue

Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Al...

Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Al...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1030c599a5ae4b4d8f002a265d9af497

Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial

About this item

Full title

Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial

Publisher

London: BioMed Central Ltd

Journal title

Alzheimer's research & therapy, 2018-01, Vol.10 (1), p.12-12, Article 12

Language

English

Formats

Publication information

Publisher

London: BioMed Central Ltd

More information

Scope and Contents

Contents

BACKGROUNDImmunotherapy targeting the amyloid-β (Aβ) peptide is a promising strategy for the treatment of Alzheimer's disease (AD); however, none of the active or passive vaccines tested have been demonstrated to be effective to date. We have developed the first active vaccine against the C-terminal end of Aβ40, ABvac40, and assessed its safety and...

Alternative Titles

Full title

Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_1030c599a5ae4b4d8f002a265d9af497

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1030c599a5ae4b4d8f002a265d9af497

Other Identifiers

ISSN

1758-9193

E-ISSN

1758-9193

DOI

10.1186/s13195-018-0340-8

How to access this item